TABLE 2.
Analysis of the clinical characteristics of patients
| Patients (n = 33) | MR4.5 | No MR4.5 | p‐value |
|---|---|---|---|
| Male | 6 | 13 | 0.8033 |
| Female | 5 | 9 | |
| Time since diagnosis (1) | |||
| <36 months | 1 | 6 | 0.4393 |
| 36 months – <60 months | 5 | 5 | |
| 60 months – <120 months | 3 | 5 | |
| 120 months | 2 | 6 | |
| Time since diagnosis (2) | |||
| 36 months – <60 months | 5 | 5 | 0.1805 |
| Others | 6 | 17 | |
| IM | 1 | 6 | 0.2284 |
| 2G‐TKI | 10 | 16 | |
| MMR, BCR‐ABL IS value ≥0.01 | 1 | 16 | 0.0006 |
| MR4, BCR‐ABL IS value <0.01 | 10 | 6 | |
| TM5614 dose | |||
| 150 mg/day | 6 | 9 | 0.4583 |
| 180 mg/day | 5 | 13 | |
Abbreviations: 2G, second‐generation; IM, imatinib; TKI, tyrosine kinase inhibitor.